Summary
14C-radiolabeled (radiocarbon) drug studies are central to defining the disposition of therapeutics in clinical development. Concerns over radiation, however, have dissuaded investigators from conducting these studies as often as their utility may merit. Accelerator mass spectrometry (AMS), originally designed for carbon dating and geochronology, has changed the outlook for in-human radiolabeled testing.
Register to download
Opportunities in low-level radiocarbon microtracing: applications and new technology
You may also be interested in:
Blog
Making Clinical Trial Recruitment More Efficient
Read Story
Poster
Predicting Screen Failure Rates of Human Abuse Potential Studies
Human Abuse Potential (HAP) studies are required for New Drug Approvals of all drugs that have a potential psychoactive effect. The steps of…
View Resource
Fact Sheet
Central Review Services
PRA's Central Review Services team, unique in the CRO industry, offers lupus-specific expertise in efficacy endpoint data correlation, standardized…
View Resource
View all related content and resources for Scientific Affairs
Explore Insights